Nike stock today: NKE slips into 2026 as rates rise and investors brace for jobs data
3 January 2026
1 min read

Nike stock today: NKE slips into 2026 as rates rise and investors brace for jobs data

NEW YORK, Jan 3, 2026, 13:54 ET — Market closed

  • Nike shares closed down 0.7% on Friday, the first U.S. session of 2026.
  • Higher Treasury yields and a firmer dollar set the tone for multinationals into the weekend.
  • Investors are watching next week’s U.S. jobs and inflation reports for clues on rate cuts and consumer demand.

Nike shares ended Friday down 0.67% at $63.28, underperforming some apparel and footwear peers on the first U.S. trading day of 2026. 1

The move matters because Nike is entering the new year still in the early stages of a turnaround, with investors balancing company-specific execution risks against a macro backdrop that is starting to move again after year-end.

U.S. stocks finished mixed on Friday as Treasury yields climbed and the dollar firmed, a combination that can weigh on global consumer brands with large overseas revenue. “Today is kind of a holiday trading day, lighter volumes, people not engaged normally,” said Jed Ellerbroek, portfolio manager at Argent Capital in St. Louis. 2

Nike traded between $62.55 and $64.13 on Friday after opening at $64.00, with about 22.3 million shares changing hands. 3

The stock’s 52-week range is $52.28 to $82.44, leaving it about 23% below its high and roughly 21% above its low based on Friday’s close. 4

Investors have also been tracking insider activity. A Form 4 filing showed CEO Elliott Hill bought 16,388 shares of Nike Class B stock on Dec. 29 at a weighted average price of $61.10, lifting his direct holdings to 241,587 shares. 5

Nike’s latest quarterly results underscored the trade-offs in its reset. The company said second-quarter revenue rose 1% to $12.4 billion, while gross margin fell 300 basis points — or 3 percentage points — to 40.6%, and earnings per share were $0.53. 6

China remains the key pressure point in the recovery narrative. Reuters reported that Nike’s sales in China fell 17% for a sixth straight quarter, while CFO Matt Friend said tariffs from Southeast Asia cost Nike $1.5 billion this year, and competition has intensified from brands such as On and Hoka. 7

The next test for the stock may come from outside the company. The U.S. employment report due Jan. 9 and the consumer price index report due Jan. 13 are expected to be major drivers for rate expectations, while investors are also watching for a U.S. Supreme Court decision on President Donald Trump’s tariffs and his choice of a new Federal Reserve chair, Reuters reported. 8

Before the next session, traders will be watching whether bond yields continue to drift higher and whether the dollar’s strength persists — both can pressure consumer discretionary names when growth expectations cool.

Nike-specific positioning is likely to stay focused on margins and demand trends rather than new headlines, with investors looking for evidence that discounting is easing and that newer product franchises can offset softness in legacy lines and slower growth in China.

Nike’s next earnings date has not been confirmed by the company, but is widely tracked around March 19, after the close, based on past reporting patterns. 9

Stock Market Today

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Bank of America stock rises as yields edge up; what could move BAC next week
Previous Story

Bank of America stock rises as yields edge up; what could move BAC next week

GE Aerospace stock jumps to a fresh 52-week high to start 2026, with earnings next in focus
Next Story

GE Aerospace stock jumps to a fresh 52-week high to start 2026, with earnings next in focus

Go toTop